Comparing predictors of conversion and decline in mild cognitive impairment

摘要: Objective: A variety of measurements have been individually linked to decline in mild cognitive impairment (MCI), but the identification optimal markers for predicting disease progression remains unresolved. The goal this study was evaluate prognostic ability genetic, CSF, neuroimaging, and obtained same participants. Methods: APOE e4 allele frequency, CSF proteins (Aβ 1-42 , total tau, hyperphosphorylated tau [p-tau 181p ]), glucose metabolism (FDG-PET), hippocampal volume, episodic memory performance were evaluated at baseline patients with amnestic MCI (n = 85), using data from a large multisite (Alzheimer9s Disease Neuroimaging Initiative). Patients classified as normal or abnormal on each predictor variable based externally derived cutoffs, then variables predictors subsequent conversion Alzheimer (AD) Assessment Scale–Cognitive Subscale) during follow-up period (1.9 ± 0.4 years). Results: converted AD an annual rate 17.2%. Subjects who had results both FDG-PET 11.7 times more likely convert than subjects measures ( p ≤ 0.02). In addition, ratio p-tau /Aβ (β 1.10 0.53; 0.04) and, marginally, predicted decline. Conclusions: Baseline predict AD, whereas longitudinal Complementary information provided by these biomarkers may aid future selection clinical trials benefit therapeutic intervention.